New Zealand markets open in 28 minutes

Laboratory Corporation of America Holdings (LH)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
200.47+0.91 (+0.46%)
At close: 04:00PM EDT
200.47 0.00 (0.00%)
After hours: 04:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close199.56
Bid197.82 x 800
Ask202.48 x 800
Day's range198.16 - 201.50
52-week range172.10 - 222.42
Avg. volume790,280
Market cap17.762B
Beta (5Y monthly)1.06
PE ratio (TTM)18.98
Earnings dateN/A
Forward dividend & yield2.88 (1.43%)
Ex-dividend date07 Aug 2023
1y target estN/A
  • GlobeNewswire

    Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

    SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company’s Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE: LH) and brings more than 30 years of experience with molecular geneti

  • GlobeNewswire

    Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp

    Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023. ASSET SALE Enzo Biochem has completed the prev

  • GlobeNewswire

    Fortrea Launches as Leading, Global Contract Research Organization Positioned to Bring Life-Changing Therapies to Patients Faster

    Company completes spin-off from Labcorp and begins trading on Nasdaq under ticker “FTRE” Independent company positioned to capitalize on growth opportunities in phases I-IV clinical trials and patient access, and to extend leading positions in oncology, clinical pharmacology and partnership models DURHAM, N.C., July 03, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has successfully completed its pre